Chairmans Address to Shareholders
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- IND approval from the FDA for theranostic SAR-Bombesin trial
- Clarity Presentation -Bell Potter Healthcare Conference 2022
- 50% recruitment reached for Phase II prostate cancer trial
- Corporate Presentation - Wilsons Drug and Device Conference
- 50% recruitment milestone reached for prostate cancer trial
Later from Clarity Pharmaceuticals
- Managing Directors Presentation to AGM
- Positive topline results from SAR-bisPSMA diagnostic trial
- Diagnostic prostate cancer trial reaches recruitment target
- PROPELLER Trial Results
- 50% recruitment milestone for NET diagnostic Phase II trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals